Eribulin is an anticancer drug marketed by Eisai Co. under the trade name Halaven. Eribulin is also known as E7389 and ER-086526, and also carries the US NCI designation NSC-707389. It is used to treat certain patients with breast cancer and liposarcoma.
Molecular Weight:
826.00222
CAS Number:
[441045-17-6]
Formula:
C40H59NO11.CH4O3S
* VAT and and shipping costs not included. Errors and price changes excepted